SAShanjana Awasthi

Shanjana Awasthi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shanjana Awasthi has a total of 79 co-authors. Here are the top co-authors by number of shared publications:

  • Vijay Ramani

    Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA

    5 shared publications
  • Stanley Kosanke

    Division of Comparative Medicine University of Oklahoma Health Sciences Center Oklahoma City OK USA

    4 shared publications
  • Vibhudutta Awasthi

    Research Imaging Facility, College of Pharmacy, University of Oklahoma Health Sciences Center , Oklahoma City, OK ; and

    4 shared publications
  • Asif Alam Chowdhury

    Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, 1110 N. Stonewall Avenue, Oklahoma City, OK-73117, USA

    3 shared publications
  • Bhupinder Singh

    Center for Animal Resources and Education, Cornell University , 300 Day Hall, Ithaca, NY 14853, USA

    3 shared publications
  • Catherine King

    Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA

    3 shared publications

Latest Publications

  • Open Access

    SPA4 peptide attenuates the accumulation of selected damage-associated molecules and pulmonary cellularity during acute Pseudomonas aeruginosa infection in mice

    by Shanjana Awasthi, Bhupinder Singh, Jun Xie

    Activation of Toll-like receptor 4 (TLR4) and accumulation of damage-associated molecular patterns (DAMPs) are hallmarks of infection and inflammation. The SPA4 peptide (amino acid sequence: GDFRYSDGTPVNYTNWYRGE) modulates TLR4-dependent host defense against Pseudomonas aeruginosa . In this study, we investigated the expression of TLR4, major DAMPs, and cellularity in the lungs of P. aeruginosa -infected mice treated with SPA4 peptide or vehicle. The expression of TLR4 and levels of DAMPs were analyzed by immunoblotting and enzyme-linked immunosorbent assay, respectively. Cellularity was determined in hematoxylin and eosin-stained lung tissue sections by microscopy. Our results demonstrated that the expression of TLR4 and DAMPs, as well as tissue cellularity, were increased in the lungs of infected mice. While P. aeruginosa -induced TLR4 expression was not affected, the levels of DAMPs were reduced in mice therapeutically treated with SPA4 peptide (fibrinogen: 8,730 ng; fibronectin: 17,925 ng; High Mobility Group Box-1 [HMGB-1]: 11,758 ng; and hyaluronan: 34,157 ng per g lung weight) compared with vehicle-treated mice (fibrinogen: 13,178 ng; fibronectin: 22,348 ng; HMGB-1: 15,896 ng; and hyaluronan: 53,644 ng per g lung weight). Correspondingly, reduced cellularity was noted in the lungs of SPA4 peptide-treated mice. These results advance our understanding of the SPA4 peptide activity against infectious stimuli.

  • Involvement of endoplasmic reticulum and histone proteins in immunomodulation by TLR4-interacting SPA4 peptide against Escherichia coli

    by Shanjana Awasthi, Bhupinder Singh, Vijay Ramani, Nachiket M. Godbole, Catherine King

    Pulmonary host defense is critical for the control of lung infection and inflammation. An increased expression and activity of Toll-like receptor 4 (TLR4) induce phagocytic uptake/clearance and inflammation against Gram-negative bacteria. In this study, we addressed the mechanistic aspect of the immunomodulatory activity of the TLR4-interacting SPA4 peptide (amino acid sequence GDFRYSDGTPVNYTNWYRGE) against Escherichia coli . Binding of the SPA4 peptide to bacteria and direct anti-bacterial effects were investigated using flow cytometric, microscopic, and bacteriological methods. The bacterial uptake and inflammatory cytokine response were studied in dendritic cells expressing endogenous basal level of TLR4 or overexpressing TLR4. The subcellular distribution and co-localization of TLR4 and bacteria were investigated by immunocytochemistry. Furthermore, we studied the cellular expression and co-localization of endoplasmic reticulum (ER) molecules (calnexin and ER membrane protein complex subunit 1; EMC1) with lysosomal-associated membrane protein 1 (LAMP1) in cells infected with E. coli and treated with the SPA4 peptide. Simultaneously, the expression of histone H2A protein was quantitated by immunoblotting. Our results demonstrate no binding or direct killing of the bacteria by SPA4 peptide. Instead, it induces the uptake and localization of E. coli in the phagolysosomes for lysis and simultaneously suppresses the secreted levels of TNF-α. Overexpression of TLR4 further augments the pro-phagocytic and anti-inflammatory activity of SPA4 peptide. A time-dependent change in subcellular distribution of TLR4 and an increased co-localization of TLR4 with E. coli in SPA4 peptide-treated cells suggest an enhanced recognition and internalization of bacteria in conjugation with TLR4. Furthermore, an increased co-localization of calnexin and EMC1 with LAMP1 indicates the involvement of ER in pro-phagocytic activity of SPA4 peptide. Simultaneous reduction in secreted amounts of TNF-α coincides with suppressed histone H2A protein expression in the SPA4 peptide-treated cells. These results provide initial insights into the plausible role of ER and histones in the TLR4-immunomodulatory activity of SPA4 peptide against Gram-negative bacteria.


  • Open Access

    Stability and structure–activity relationship of the SPA4 peptide under ambient and stressed conditions of lung injury

    by Asif Alam Chowdhury, Karla Rodgers, Nachiket M. Godbole, Shanjana Awasthi

    Presented work in this article describes the structure of SPA4 peptide in ambient conditions, simulated lung fluids and chemical components, and structure–activity relation of SPA4 peptide against lipopolysaccharide stimuli.


  • Open Access

    Effects of SPA4 peptide on lipopolysaccharide‐disrupted lung epithelial barrier, injury, and function in a human cell system and mouse model of lung injury

    by Asif Alam Chowdhury, Nachiket M. Godbole, Neha Chataut, Stanley Kosanke, Karla Rodgers, Shanjana Awasthi

    Disrupted epithelial barrier, fluid accumulation, inflammation, and compromised physiology are hallmarks of lung injury. Here we investigated the structural stability of the Toll-like receptor-4 (TLR4)-interacting SPA4 peptide, its effect on Pseudomonas aeruginosa lipopolysaccharide (LPS)-disrupted epithelial barrier in a human cell system, and lung injury markers in a mouse model of LPS-induced lung inflammation. The structural properties of SPA4 peptide were investigated using circular dichroism and UV-VIS spectroscopy. The transepithelial electrical resistance (TEER), an indicator of barrier function, was measured after the cells were challenged with 1 mu g/ml LPS and treated with 10 or 100 mu M SPA4 peptide. The expression and localization of tight junction proteins were studied by immunoblotting and immunocytochemistry, respectively. Mice were intratracheally challenged with 5 mu g LPS per g body weight and treated with 50 mu g SPA4 peptide. The lung wet/dry weight ratios or edema, surfactant protein-D (SP-D) levels in serum, lung function, tissue injury, body weights, and temperature, and survival were determined as study parameters. The spectroscopy results demonstrated that the structure was maintained among different batches of SPA4 peptide throughout the study. Treatment with 100 mu M SPA4 peptide restored the LPS-disrupted epithelial barrier, which correlated with the localization pattern of Zonula Occludens (ZO)-1 and occludin proteins. Correspondingly, SPA4 peptide treatment helped suppress the lung edema and levels of serum SP-D, improved some of the lung function parameters, and reduced the mortality risk against LPS challenge. Our results suggest that the anti-inflammatory activity of the SPA4 peptide facilitates the resolution of lung pathology.


  • Tight Junctions, the Epithelial Barrier, and Toll-like Receptor-4 During Lung Injury

    by Nachiket M. Godbole, Asif Alam Chowdhury, Neha Chataut, Shanjana Awasthi

    — Lung epithelium is constantly exposed to the environment and is critically important for the orchestration of initial responses to infectious organisms, toxins, and allergic stimuli, and maintenance of normal gaseous exchange and pulmonary function. The integrity of lung epithelium, fluid balance, and transport of molecules is dictated by the tight junctions (TJs). The TJs are formed between adjacent cells. We have focused on the topic of the TJ structure and function in lung epithelial cells. This review includes a summary of the last twenty years of literature reports published on the disrupted TJs and epithelial barrier in various lung conditions and expression and regulation of specific TJ proteins against pathogenic stimuli. We discuss the molecular signaling and crosstalk among signaling pathways that control the TJ structure and function. The Toll-like receptor-4 (TLR4) recognizes the pathogen- and damage-associated molecular patterns released during lung injury and inflammation and coordinates cellular responses. The molecular aspects of TLR4 signaling in the context of TJs or the epithelial barrier are not fully known. We describe the current knowledge and possible networking of the TLR4-signaling with cellular and molecular mechanisms of TJs, lung epithelial barrier function, and resistance to treatment strategies.


  • Open Access

    Mechanism of Anti-Inflammatory Activity of TLR4-Interacting SPA4 Peptide

    by Shanjana Awasthi, Gaurav Kumar, Vijay Ramani, Vibhudutta Awasthi, Karla K. Rodgers, Jun Xie, Jacob Beierle, Gertrude Kyere-Davies, Bhupinder Singh, Negar Rahman, et al.

    The TLR4-interacting SPA4 peptide suppresses inflammation. We assessed the structural and physicochemical properties and binding of SPA4 peptide to TLR4–MD2. We also studied the changes at the whole transcriptome level, cell morphology, viability, secreted cytokines and chemokines, and cell influx in cell systems and mouse models challenged with LPS and treated with SPA4 peptide. Our results demonstrated that the SPA4 peptide did not alter the cell viability and size and only moderately affected the transcriptome of the cells. Computational docking and rendering suggested that the SPA4 peptide intercalates with LPS-induced TLR4–MD2 complex. Results with alanine mutations of D-2 amino acid and NYTXXXRG-12-19 motif of SPA4 peptide suggested their role in binding to TLR4 and in reducing the cytokine response against LPS stimulus. Furthermore, therapeutically administered SPA4 peptide significantly suppressed the secreted levels of cytokines and chemokines in cells and bronchoalveolar lavage fluids of LPS-challenged mice. The results suggest that the SPA4 peptide intercalates with LPS-induced TLR4 complex and signaling for the suppression of inflammation.


  • Open Access

    Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report

    by Charles S. Dela Cruz, Scott E. Evans, Marcos I. Restrepo, Nathan Dean, Antonio Torres, Isabel Amara-Elori, Shanjana Awasthi, Elisabet Caler, Bin Cao, James D. Chalmers, et al.

    Pneumonia causes a significant burden of disease worldwide. Although all populations are at risk of pneumonia, those at extremes of age and those with immunosuppressive disorders, underlying respiratory disease, and critical illness are particularly vulnerable. Although clinical practice guidelines addressing the management and treatment of pneumonia exist, few of the supporting studies focus on the crucial contributions of the host in pneumonia pathogenesis and recovery. Such essential considerations include the host risk factors that lead to susceptibility to lung infections; biomarkers reflecting the host response and the means to pursue host-directed pneumonia therapy; systemic effects of pneumonia on the host; and long-term health outcomes after pneumonia. To address these gaps, the Pneumonia Working Group of the Assembly on Pulmonary Infection and Tuberculosis led a workshop held at the American Thoracic Society meeting in May 2018 with overarching objectives to foster attention, stimulate research, and promote funding for short-term and long-term investigations into the host contributions to pneumonia. The workshop involved participants from various disciplines with expertise in lung infection, pneumonia, sepsis, immunocompromised patients, translational biology, data science, genomics, systems biology, and clinical trials. This workshop report summarizes the presentations and discussions and important recommendations for future clinical pneumonia studies. These recommendations include establishing consensus disease and outcome definitions, improved phenotyping, development of clinical study networks, standardized data and biospecimen collection and protocols, and development of innovative trial designs.


  • Open Access

    Lung and general health effects of Toll-like receptor-4 (TLR4)-interacting SPA4 peptide

    by Shanjana Awasthi, Negar Rahman, Bin Rui, Gaurav Kumar, Vibhudutta Awasthi, Melanie Breshears, Stanley Kosanke

    Background: A surfactant protein-A-derived peptide, which we call SPA4 peptide (amino acids: GDFRYSDGTPVNYTNWYRGE), alleviates lung infection and inflammation. This study investigated the effects of intratracheally administered SPA4 peptide on systemic, lung, and health parameters in an outbred mouse strain, and in an intratracheal lipopolysaccharide (LPS) challenge model. Methods: The outbred CD-1 mice were intratracheally administered with incremental doses of SPA4 peptide (0.625–10 μg/g body weight) once every 24 h, for 3 days. Mice left untreated and those treated with vehicle were included as controls. Mice were euthanized after 24 h of last administration of SPA4 peptide. In order to assess the biological activity of SPA4 peptide, C57BL6 mice were intratracheally challenged with 5 μg LPS/g body weight and treated with 50 μg SPA4 peptide via intratracheal route 1 h post LPS-challenge. Mice were euthanized after 4 h of LPS challenge. Signs of sickness and body weights were regularly monitored. At the time of necropsy, blood and major organs were harvested. Blood gas and electrolytes, serum biochemical profiles and SPA4 peptide-specific immunoglobulin G (IgG) antibody levels, and common lung injury markers (levels of total protein, albumin, and lactate, lactate dehydrogenase activity, and lung wet/dry weight ratios) were determined. Lung, liver, spleen, kidney, heart, and intestine were examined histologically. Differences in measured parameters were analyzed among study groups by analysis of variance test. Results: The results demonstrated no signs of sickness or changes in body weight over 3 days of treatment with various doses of SPA4 peptide. It did not induce any major toxicity or IgG antibody response to SPA4 peptide. The SPA4 peptide treatment also did not affect blood gas, electrolytes, or serum biochemistry. There was no evidence of injury to the tissues and organs. However, the SPA4 peptide suppressed the LPS-induced lung inflammation. Conclusions: These findings provide an initial toxicity profile of SPA4 peptide. Intratracheal administration of escalating doses of SPA4 peptide does not induce any significant toxicity at tissue and organ levels. However, treatment with a dose of 50 μg SPA4 peptide, comparable to 2.5 μg/g body weight, alleviates LPS-induced lung inflammation.


  • Dendritic cell-based immunization induces Coccidioides Ag2/PRA-specific immune response

    by Shanjana Awasthi, Prachi Vilekar, Alexandra Conkleton, Negar Rahman